Dexamethasone (or equivalent)

DRUG4 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Esophageal Squamous Cell CarcinomaFallopian Tube CancerLung Neoplasm MalignantNon-small Cell Lung Cancer (NSCLC)Ovarian CancerPrimary Peritoneal Cancer

Phase 1

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

RecruitingNCT05319730

Merck Sharp & Dohme LLCEsophageal Squamous Cell Carcinoma

Start: 2023-05-16End: 2029-04-10Target: 230Updated: 2026-03-20

Phase 2

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

RecruitingNCT06788912

Merck Sharp & Dohme LLCLung Neoplasm Malignant

Start: 2025-03-20End: 2032-02-06Target: 60Updated: 2026-03-31

Phase 3

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

RecruitingNCT06305754

Merck Sharp & Dohme LLCNon-small Cell Lung Cancer (NSCLC)

Start: 2024-06-11End: 2030-06-14Target: 520Updated: 2026-04-02

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

RecruitingNCT06824467

Merck Sharp & Dohme LLCFallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer

Start: 2025-04-09End: 2032-11-09Target: 770Updated: 2026-04-02

Related Papers

Sacituzumab tirumotecan versus docetaxel for previously treated <i>EGFR</i> -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial

BMJ2025-06-0514 citations

KEYMAKER-U01E: A phase 2 umbrella study with rolling arms of investigational agents with or without chemotherapy plus pembrolizumab for resectable stage II–IIIB (N2) non–small-cell lung cancer (NSCLC).

Journal of Clinical Oncology2025-05-28